B Escudier

Summary

Affiliation: Institut Gustave Roussy
Country: France

Publications

  1. ncbi request reprint Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma
    Bernard Escudier
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Clin Cancer Res 13:1801-9. 2007
  2. ncbi request reprint Phase II results of Dovitinib (TKI258) in patients with metastatic renal cell cancer
    Bernard Escudier
    Authors Affiliations Institut de cancérologie Gustave Roussy, Villejuif Hôpital Saint André, Bordeaux University Hospital, Bordeaux, France Medizinische Hochschule Hannover, Hannover Technische Universität München, Munich, Germany Taichung Veterans General Hospital, National Yang Ming University School of Medicine National Taiwan University Hospital, Taipei, Taiwan 12 de Octubre University Hospital, Madrid, Spain University of California, San Francisco, San Francisco, California Novartis Pharmaceuticals Corporation, East Hanover, New Jersey and Novartis Pharma AG, Basel, Switzerland
    Clin Cancer Res 20:3012-22. 2014
  3. doi request reprint Optimal management of metastatic renal cell carcinoma: current status
    Bernard Escudier
    Institut Gustave Roussy, 114 rue Edouard Vaillant, 94805 Villejuif, France
    Drugs 73:427-38. 2013
  4. ncbi request reprint How to select amongst available options for the treatment of advanced RCC?
    B Escudier
    Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif 94800, France
    Ann Oncol 23:x309-12. 2012
  5. ncbi request reprint Emerging immunotherapies for renal cell carcinoma
    B Escudier
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif Paris Sud, France
    Ann Oncol 23:viii35-40. 2012
  6. ncbi request reprint Advanced renal cell carcinoma: current and emerging management strategies
    Bernard Escudier
    Institut Gustave Roussy, Villejuif, France
    Drugs 67:1257-64. 2007
  7. ncbi request reprint [Metastatic renal cell carcinoma and its treatments]
    B Escudier
    Unité d Immunothérapie, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif, France
    Ann Urol (Paris) 40:S82-5. 2006
  8. doi request reprint Sunitinib for the management of advanced renal cell carcinoma
    Bernard Escudier
    Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Expert Rev Anticancer Ther 10:305-17. 2010
  9. ncbi request reprint Sorafenib in advanced clear-cell renal-cell carcinoma
    Bernard Escudier
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    N Engl J Med 356:125-34. 2007
  10. doi request reprint Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival
    Bernard Escudier
    Unité Immunothérapie, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    J Clin Oncol 28:2144-50. 2010

Detail Information

Publications92

  1. ncbi request reprint Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma
    Bernard Escudier
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Clin Cancer Res 13:1801-9. 2007
    ..To determine the safety, maximum tolerated dose, pharmacokinetics, and efficacy, and to evaluate biomarkers, of the multikinase inhibitor sorafenib plus IFN alpha-2a in advanced renal cell carcinoma (RCC) or melanoma...
  2. ncbi request reprint Phase II results of Dovitinib (TKI258) in patients with metastatic renal cell cancer
    Bernard Escudier
    Authors Affiliations Institut de cancérologie Gustave Roussy, Villejuif Hôpital Saint André, Bordeaux University Hospital, Bordeaux, France Medizinische Hochschule Hannover, Hannover Technische Universität München, Munich, Germany Taichung Veterans General Hospital, National Yang Ming University School of Medicine National Taiwan University Hospital, Taipei, Taiwan 12 de Octubre University Hospital, Madrid, Spain University of California, San Francisco, San Francisco, California Novartis Pharmaceuticals Corporation, East Hanover, New Jersey and Novartis Pharma AG, Basel, Switzerland
    Clin Cancer Res 20:3012-22. 2014
    ....
  3. doi request reprint Optimal management of metastatic renal cell carcinoma: current status
    Bernard Escudier
    Institut Gustave Roussy, 114 rue Edouard Vaillant, 94805 Villejuif, France
    Drugs 73:427-38. 2013
    ..Finally, optimal therapy for non-clear cell RCC remains to be delineated, although sunitinib, everolimus and other VEGFR-TKI or mTOR inhibitors have all demonstrated modest benefit...
  4. ncbi request reprint How to select amongst available options for the treatment of advanced RCC?
    B Escudier
    Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif 94800, France
    Ann Oncol 23:x309-12. 2012
    ..The different options are described in this manuscript...
  5. ncbi request reprint Emerging immunotherapies for renal cell carcinoma
    B Escudier
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif Paris Sud, France
    Ann Oncol 23:viii35-40. 2012
    ..Novel therapies used in combination or sequentially have the potential to improve outcomes in mRCC, and results from ongoing/planned trials will shape future therapy...
  6. ncbi request reprint Advanced renal cell carcinoma: current and emerging management strategies
    Bernard Escudier
    Institut Gustave Roussy, Villejuif, France
    Drugs 67:1257-64. 2007
    ..However, many questions still remain regarding the efficacy of combination treatments and on the best way to achieve complete remission, which is probably the best hope of curing MRCC...
  7. ncbi request reprint [Metastatic renal cell carcinoma and its treatments]
    B Escudier
    Unité d Immunothérapie, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif, France
    Ann Urol (Paris) 40:S82-5. 2006
    ....
  8. doi request reprint Sunitinib for the management of advanced renal cell carcinoma
    Bernard Escudier
    Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Expert Rev Anticancer Ther 10:305-17. 2010
    ..This paper presents an overview of data supporting the use of sunitinib for mRCC, and considers the optimal management of sunitinib in clinical practice...
  9. ncbi request reprint Sorafenib in advanced clear-cell renal-cell carcinoma
    Bernard Escudier
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    N Engl J Med 356:125-34. 2007
    ..We conducted a phase 3, randomized, double-blind, placebo-controlled trial of sorafenib, a multikinase inhibitor of tumor-cell proliferation and angiogenesis, in patients with advanced clear-cell renal-cell carcinoma...
  10. doi request reprint Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival
    Bernard Escudier
    Unité Immunothérapie, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    J Clin Oncol 28:2144-50. 2010
    ..A phase III trial of bevacizumab combined with interferon alfa-2a (IFN) showed significant improvements in progression-free survival (PFS) in metastatic renal cell carcinoma (mRCC). Here, we report overall survival (OS) data...
  11. doi request reprint Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial
    Bernard Escudier
    Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 27:3312-8. 2009
    ....
  12. ncbi request reprint Phase II trial of thalidomide in renal-cell carcinoma
    B Escudier
    Institut Gustave Roussy, Villejuif, France
    Ann Oncol 13:1029-35. 2002
    ..Thalidomide has been reported to yield anti-tumor activity in cancer. We performed a phase II trial of this drug in patients with metastatic renal cell carcinoma to determine its efficacy...
  13. ncbi request reprint Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'Immunothérape
    B Escudier
    Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 17:2039-43. 1999
    ..To determine whether either of these cytokines might be efficient after failure of the other, we analyzed a series of patients treated with either IL-2 or IFNalpha2a as second-line treatment after failure of the other cytokine...
  14. doi request reprint [Treatment of metastatic kidney cancer in elderly subjects]
    B Escudier
    Unité d Immunothérapie, Institut Gustave Roussy, rue Camille Desmoulins, 94805 Villejuif, France
    Prog Urol 19:S129-32. 2009
    ..Given the data available today, no dose adaptation in relation to age is recommended in metastatic renal cancer...
  15. ncbi request reprint Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
    Bernard Escudier
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Lancet 370:2103-11. 2007
    ..Therefore, an investigation of the combination treatment of the humanised anti-VEGF monoclonal antibody bevacizumab with interferon alfa was warranted...
  16. doi request reprint Vascular endothelial growth factor-targeted therapy for the treatment of renal cell carcinoma
    Bernard Escudier
    Institut Gustave Roussy, Villejuif, France
    Drugs 71:1179-91. 2011
    ..Ongoing trials evaluating novel anti-VEGF therapies could establish whether the increased potency and selectivity of these agents results in improved efficacy and tolerability in RCC patients, further improving their prognosis...
  17. doi request reprint Sorafenib for the management of advanced renal cell carcinoma
    Bernard Escudier
    Institut Gustave Roussy, 39 rue Camille Desmoulins, Villejuif 94805, France
    Expert Rev Anticancer Ther 11:825-36. 2011
    ..This article reviews the expansive clinical evidence supporting the use of sorafenib in RCC, including analyses across a variety of subpopulations, and examines the impact of sorafenib on clinical practice and its future role in RCC...
  18. doi request reprint Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma
    Bernard Escudier
    Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805, Villejuif, France
    J Clin Oncol 27:1280-9. 2009
    ....
  19. doi request reprint Sequential therapy in renal cell carcinoma
    Bernard Escudier
    Medical Oncology Department, Institut Gustave Roussy, Villejuif, France
    Cancer 115:2321-6. 2009
    ..Expecting a survival of 40 months does appear possible based on currently available data, although this assumption will have to be proven in the future...
  20. doi request reprint [Targeted therapies: sequential and combined treatments]
    M Gross-Goupil
    Institut Gustave Roussy, 114, rue Edouard Vaillant, 94805, Villejuif, France
    Bull Cancer 97:65-71. 2010
    ....
  21. doi request reprint [Renal cell carcinoma management and therapies in 2010]
    B Albouy
    Institut Gustave Roussy, Departement de Medecine, 39, rue Camille Desmoulins, 94805 Villejuif, France
    Bull Cancer 97:17-28. 2010
    ..Prospective trials will be assessed the value of nephrectomy in patients treated by antiangiogenic therapies. Large randomized trial are ongoing to evaluate these new therapies in adjuvant setting...
  22. doi request reprint Sequential sorafenib and sunitinib for renal cell carcinoma
    M P Sablin
    Institut Gustave Roussy, Villejuif, France
    J Urol 182:29-34; discussion 34. 2009
    ..In many patients sequential administration of the 2 drugs occurs because of the lack of sustained efficacy of the first agent. We determined the efficacy and safety of sequential administration...
  23. ncbi request reprint Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer
    S Rajpar
    Department of Medicine, Institut Gustave Roussy, University of Paris XI, Villejuif, France
    Ann Oncol 21:1864-9. 2010
    ..The aim of this study was to assess the prognostic value of uNTx for overall survival (OS) and the incidence of SRE in patients with bone metastases from CRPC receiving zoledronic acid...
  24. ncbi request reprint Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network
    G G Malouf
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 21:1834-8. 2010
    ..We analyzed the benefit of targeted therapy [vascular endothelial growth factor receptor (VEGFR)-targeted agents and/or mammalian target of rapamycin (mTOR) inhibitors] in these patients...
  25. ncbi request reprint [New drugs in metastatic castration-resistant prostate cancer]
    L Albiges
    Institut Gustave Roussy, Departement de Medecine, 39 rue Camille Desmoulins, 94800 Villejuif, France
    Bull Cancer 97:149-59. 2010
    ..A recent analogue of thalidomide, probably more efficient, lenalidomide is also in development...
  26. ncbi request reprint Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie
    A Ravaud
    Department of Medicine, Institut Bergonie, Bordeaux, France
    J Clin Oncol 16:2728-32. 1998
    ..A phase II trial was designed to determine the efficacy and the tolerance of interleukin-2 (IL-2), interferon alfa-2a (IFNalpha), and fluorouracil (5-FU) in patients with metastatic renal cell carcinoma...
  27. doi request reprint Incidence of brain metastases in renal cell carcinoma treated with sorafenib
    C Massard
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 21:1027-31. 2010
    ..i.d.), versus placebo in the phase III Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGET)...
  28. ncbi request reprint Novel and bone-targeted agents for CRPC
    K Fizazi
    Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif 94800, France
    Ann Oncol 23:x264-7. 2012
    ..benefit? Can we personalise treatment based on the biology of the individual's disease? How will we develop new active compounds in the context where a half dozen approved agents may confound their potential overall survival effect?..
  29. doi request reprint Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features
    Y Loriot
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 20:703-8. 2009
    ..The purpose of this study was to prospectively assess the anticancer activity and tolerance of the carboplatin-etoposide combination in this setting while evaluating neuroendocrine (NE) features...
  30. doi request reprint The postchemotherapy PSA surge syndrome
    R Thuret
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 19:1308-11. 2008
    ..The objective of this work was to study early serum PSA changes in patients under chemotherapy and to correlate these changes with subsequent response assessment...
  31. doi request reprint How to select targeted therapy in renal cell cancer
    B Escudier
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 21:vii59-62. 2010
    ..In addition, in front of every patient, the physician will need to raise important questions such as whether the patient should be treated, should receive surgery and also what is his prognosis. The different options are described here...
  32. ncbi request reprint Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma
    S Antoun
    Department of Supportive Care, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 21:1594-8. 2010
    ..Patients with severe depletion of skeletal muscle (sarcopenia) are prone to dose-limiting toxicity (DLT) during fluoropyrimidine therapy. We hypothesized that sarcopenia may also predict toxicity of targeted therapy drugs...
  33. doi request reprint Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib
    B Beuselinck
    Department of Medical Oncology, Hopital Europeen Georges Pompidou, Assistance Publique Hopitaux de Paris, Paris, France
    Ann Oncol 22:794-800. 2011
    ..The aim of our study was to determine whether the presence of bone metastases affects outcomes in patients with metastatic clear-cell renal cell carcinoma (m-ccRCC) receiving sunitinib...
  34. doi request reprint Sexual life of male patients with advanced renal cancer treated with angiogenesis inhibitors
    T Bessede
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 22:2320-4. 2011
    ..The objective of the study was to investigate possible sexual disorders in a male population with advanced RCC treated with a molecular targeted therapy (MTT)...
  35. ncbi request reprint To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound
    Michele Lamuraglia
    Department of Medical Imaging, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Eur J Cancer 42:2472-9. 2006
    ....
  36. ncbi request reprint [Eruptive nevi associated with sorafenib treatment]
    M Bennani-Lahlou
    Institut Gustave Roussy, 39 rue Camille Desmoulins, Villejuif Cedex, France
    Ann Dermatol Venereol 135:672-4. 2008
    ..Cutaneous side effects are frequent with sorafenib, but no naevus modification has been reported until now...
  37. ncbi request reprint Sorafenib [corrected] in kidney cancer
    B Escudier
    Institut Gustave Roussy, Villejuif, France
    Ann Oncol 18:ix90-3. 2007
  38. ncbi request reprint Poor prognosis nonseminomatous germ-cell tumours (NSGCTs): should chemotherapy doses be reduced at first cycle to prevent acute respiratory distress syndrome in patients with multiple lung metastases?
    C Massard
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 21:1585-8. 2010
    ..The management of these patients was modified at Institut Gustave Roussy in 1997 to try to avoid this complication...
  39. doi request reprint Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor
    Julien Autier
    Dermatology Unit, Gustave Roussy Institute, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Arch Dermatol 144:886-92. 2008
    ..To provide an accurate description and to evaluate the incidence and severity of cutaneous reactions induced by sorafenib tosylate, a new oral multikinase inhibitor...
  40. pmc Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors
    F Farace
    Translational Research Laboratory, Institut de Cancerologie Gustave Roussy, 114 rue Edouard Vaillant, 94805 Villejuif, France
    Br J Cancer 104:1144-50. 2011
    ....
  41. doi request reprint Randomized study of intravenous versus subcutaneous interleukin-2, and IFNalpha in patients with good prognosis metastatic renal cancer
    Sylvie Negrier
    Universite de Lyon, Centre Leon Berard, Medical Oncology Department, Institut National de la Sante et de la Recherche Medicale U 590 and Biostatistics Unit, Centre Leon Berard, Lyon Cedex 08, France
    Clin Cancer Res 14:5907-12. 2008
    ..A French immunotherapy intergroup multicenter trial assessed the potential benefit of i.v. over s.c. administration of IL-2 in this combination...
  42. ncbi request reprint The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer
    Yohann Loriot
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Eur J Cancer 46:1770-2. 2010
    ..The interval from the last cycle of first-line docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel...
  43. ncbi request reprint Exosomes for cancer immunotherapy
    F Andre
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 15:iv141-4. 2004
  44. doi request reprint Signaling inhibitors in metastatic renal cell carcinoma
    Bernard Escudier
    Institut Gustave Roussy, Villejuif, France
    Cancer J 14:325-9. 2008
    ..However, many questions still remain on the efficacy of combination treatments and on the best way to get complete remission, which is probably the best way to lead to cure of metastatic renal cell cancer in the future...
  45. ncbi request reprint Bevacizumab: direct anti-VEGF therapy in renal cell carcinoma
    Bernard Escudier
    Immunotherapy Unit, Institut Gustave Roussy, Villejuif Cedex, France
    Expert Rev Anticancer Ther 8:1545-57. 2008
    ..Trials over the next 5 years will guide clinical practice, but bevacizumab plus IFN is currently a standard first-line option for mRCC...
  46. doi request reprint Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study
    Sami Antoun
    Department of Supportive Care, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    J Clin Oncol 28:1054-60. 2010
    ..Muscle loss is specifically exacerbated by sorafenib, consistent with the evidence for a role of kinases in regulating muscle mass. Muscle loss is a sorafenib adverse effect that may relate to asthenia, fatigue, and physical disability...
  47. doi request reprint Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer
    Karim Fizazi
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 27:2429-35. 2009
    ..To assess docetaxel combined with samarium-153-ethylene diamine tetramethylene phosphonic acid (EDTMP), a radiopharmaceutical with a high affinity for bone, in patients with castration-resistant prostate cancer (CRPC)...
  48. ncbi request reprint Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma
    Bernard Escudier
    Unité Immunothérapie, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    J Clin Oncol 27:4068-75. 2009
    ..Herein, we report results of an open-label, multicenter phase II mRCC study of sunitinib administered on a continuous once-daily dosing regimen...
  49. ncbi request reprint Cutaneous side-effects of kinase inhibitors and blocking antibodies
    Caroline Robert
    Department of Medical Oncology, Dermatology Unit, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94801Villejuif Cedex, France
    Lancet Oncol 6:491-500. 2005
    ..Elucidation of this connection could lead to the identification of crucial predictive factors for tumour response...
  50. ncbi request reprint Development and validation of a real-time PCR assay for the detection and quantitation of p53 recombinant adenovirus in clinical samples from patients treated with Ad5CMV-p53 (INGN 201)
    Patrick Saulnier
    Centre de Référence IGR Aventis Gencell, Institut Gustave Roussy, 39, rue Camille Desmoulins, F 94805 Villejuif, France
    J Virol Methods 114:55-64. 2003
    ....
  51. ncbi request reprint Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study
    Stephane Oudard
    Medical Oncology Department, Georges Pompidou European Hospital, Rene Descartes University, Paris, France
    J Urol 177:1698-702. 2007
    ....
  52. ncbi request reprint A phase II study of irinotecan in patients with advanced renal cell carcinoma
    Karim Fizazi
    Département de Médecine Institut Gustave Roussy, Villejuif, France
    Cancer 98:61-5. 2003
    ..Therefore, the authors tested the antitumor activity of irinotecan in patients with RCC...
  53. ncbi request reprint Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941
    Bernard Escudier
    Institut Gustave Roussy, Villejuif, France
    J Urol 178:1901-5. 2007
    ..We analyzed prognostic factors, described survival and generated a prognostic model in patients with metastatic renal cell carcinoma in whom immunotherapy failed and who were potentially eligible for novel agents...
  54. ncbi request reprint [Interest of color Doppler ultrasonography to evaluate a new anti-angiogenic treatment with thalidomide in metastatic renal cell carcinoma]
    Nathalie Lassau
    Unité d échographie, Departement d Imagerie, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Bull Cancer 91:629-35. 2004
    ..Twenty eight had tumor targets which could be evaluated by DUS. Before treatment, the volume was studied in 59 tumors and the vascularity in 54 tumors. During treatment, comparative DUS examinations were performed every 6 weeks...
  55. ncbi request reprint Peripheral gammadelta T-lymphocytes as an innovative tool in immunotherapy for metastatic renal cell carcinoma
    Emilie Viey
    Institut National de la Santé et de la Recherche Médicale U487IFR 54, Institut Gustave Roussy, 94805 Villejuif, France
    Expert Rev Anticancer Ther 5:973-86. 2005
    ....
  56. doi request reprint Dermatologic symptoms associated with the multikinase inhibitor sorafenib
    Caroline Robert
    Department of Medicine, Dermatology Unit, Institut Gustave Roussy, Villejuif, France
    J Am Acad Dermatol 60:299-305. 2009
    ..The multikinase inhibitor sorafenib (Nexavar) is associated with a relatively high incidence of dermatologic symptoms...
  57. pmc Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma
    A Saroufim
    1 INSERM U753, Institut Gustave Roussy, 114 rue Edouard Vaillant, 94800 Villejuif, France 2 Medical Oncology department, Institut Gustave Roussy, 114 rue Edouard Vaillant, 94800 Villejuif, France
    Br J Cancer 110:1778-84. 2014
    ..Recently, CD105 has been described as a RCC cancer stem cell marker...
  58. ncbi request reprint High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activity
    K Fizazi
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 18:518-21. 2007
    ..Telomerase activation, one of the major immortalization events, is found in most cases of prostate cancer. We attempted to develop a method using telomerase activity to isolate CTCs in patients with prostate cancer...
  59. ncbi request reprint Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers
    B Escudier
    Institut Gustave Roussy, Villejuif, Centre Leon Berard, Lyon, France
    J Urol 168:959-61. 2002
    ..We assessed the efficacy and toxicity of a chemotherapy regimen combining doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma...
  60. doi request reprint Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma
    Judith Michels
    Institut Gustave Roussy, Departement de Medecine, Villejuif, France
    Invest New Drugs 28:690-3. 2010
    ..Tumor lysis syndrom can occur in solid tumors. We report a case of patient with metastatic RCC treated with sunitinib with a diagnosis of tumor lysis syndrome...
  61. ncbi request reprint Recombinant adenovirus shedding after intratumoral gene transfer in lung cancer patients
    F Griscelli
    Department of Biology, Institut Gustave Roussy, Villejuif, France
    Gene Ther 10:386-95. 2003
    ..In addition, only on the day of the injection was Ad.RSVbetagal also detected in E1-positive PBL, indicating that virus replication in blood was very unlikely...
  62. ncbi request reprint The sensitivity of renal cell carcinoma cells to interferon alpha correlates with p53-induction and involves Bax
    S Wittnebel
    INSERM Unité 487, Cytokines et Immunologie des Tumeurs Humaines, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex
    Eur Cytokine Netw 16:123-7. 2005
    ..Our results suggest a role of p53 and its downstream target Bax, in the control of RCC sensitivity to IFN-alpha...
  63. ncbi request reprint CD158 receptor controls cytotoxic T-lymphocyte susceptibility to tumor-mediated activation-induced cell death by interfering with Fas signaling
    Asma Gati
    Institut National de la Santé et de la Recherche Médicale INSERM U487, Institut Fédératif de Recherche 54, 94805 Villejuif, France
    Cancer Res 63:7475-82. 2003
    ..These studies provide evidence that tumor cells selectively favor the local persistence of nonfunctional KIR+ CTLs by promoting their survival...
  64. ncbi request reprint Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma
    Emilie Viey
    Institut National de la Santé et de la Recherche Médicale Unité 487, Institut Fédératif de Recherche 54, Institut Gustave Roussy, Villejuif, France
    J Immunol 174:1338-47. 2005
    ..These results outline that Vgamma9Vdelta2-TCR effectors may represent a promising approach for the treatment of metastatic renal cell carcinoma...
  65. ncbi request reprint Analysis of the natural killer mediated immune response in metastatic renal cell carcinoma patients
    Asma Gati
    INSERM, Institut Gustave Roussy, Villejuif, France
    Int J Cancer 109:393-401. 2004
    ..Although LFA-1/ICAM-1 interaction potentiates RCC cell lysis, HLA-I/NKR interaction clearly decreased RCC cell susceptibility to NK cells. In addition, proliferation of NK cells from MRCC patients in response to cytokines was altered...
  66. pmc Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha
    Sophie Viaud
    Institut National de la Sante et de la Recherche Medicale, Unité 805, Villejuif, France
    PLoS ONE 4:e4942. 2009
    ..Altogether, these data provide a mechanistic explanation on how Dex may stimulate non MHC restricted-anti-tumor effectors and induce tumor regression in vivo...
  67. ncbi request reprint Engagement of the inhibitory receptor CD158a interrupts TCR signaling, preventing dynamic membrane reorganization in CTL/tumor cell interaction
    Nadia Guerra
    Institut National de la Santé et de la Recherche Médicale INSERM U487 and Unité des Thérapies innovantes, Institut Gustave Roussy, and Institut Andre Lwoff CNRS, Hopital Paul Brousse, Villejuif, France
    Blood 100:2874-81. 2002
    ..Accordingly, the expression of CD158 by TILs may favor tumor cell escape to the immune response...
  68. ncbi request reprint [Exosomes and anti-tumour immunotherapy]
    Nathalie Chaput
    Unite d immunologie, Departement de Biologie Clinique, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Bull Cancer 90:695-8. 2003
    ..Here, we will focus on the biological features pertaining to dendritic cell- and tumor cell derived-exosomes and will discuss their potential clinical implementation...
  69. ncbi request reprint Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie
    Sylvie Negrier
    Cytokines and Cancer Research Unit, INSERM U 590 and Medical Oncology Department, Cedex 08, France
    J Clin Oncol 22:2371-8. 2004
    ..Our objective was to analyze the prognostic value of circulating vascular endothelial growth factor (VEGF), interleukin-10 (IL-10), and interleukin-6 (IL-6)...
  70. ncbi request reprint [Metastatic kidney cancer: new therapeutic approaches]
    Sylvie Negrier
    Departement d Oncologie Medicale, Centre Leon Berard, 28, rue Laennec, 69373 Lyon, France
    Prog Urol 12:703-8. 2002
    ..Finally, various molecules with promising antiangiogenic properties are currently under development in renal cancer...
  71. ncbi request reprint Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels
    Christoph Rochlitz
    Departement Innere Medizin, Abteilung für Onkologie, Kantonsspital, Petersgraben 4, CH 4031 Basel, Switzerland
    Cancer Gene Ther 9:289-95. 2002
    ..The objectives of this study were to evaluate the tolerance and incidence of tumor regression in patients with metastatic melanoma, following repeated administration of Vero-IL-2 cells...
  72. pmc CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner
    Francois Ghiringhelli
    ERM 0208, Institut National de la Sante et de la Recherche Medicale INSERM, University of Paris XI, France
    J Exp Med 202:1075-85. 2005
    ..Human NK cell-mediated tumor recognition could also be restored by depletion of T reg cells from tumor-infiltrating lymphocytes. These findings support a role for T reg cells in blunting the NK cell arm of the innate immune system...
  73. doi request reprint Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded Vgamma9Vdelta2 T cells from renal cell carcinoma patients
    Emilie Viey
    Institut National de la Santé et de la Recherche Médicale U753, from Institut Fédératif de Recherche 54 Villejuif, France
    J Immunother 31:313-23. 2008
    ....
  74. ncbi request reprint Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial
    Sylvie Negrier
    Universite de Lyon, Department of Medical Oncology and Cytokines and Cancer Research Unit, Leon Berard Center, INSERM U590, Lyon, France
    Cancer 110:2468-77. 2007
    ..The Programme Etude Rein Cytokines (PERCY) Quattro trial was designed to evaluate both cytokines for their survival benefit to intermediate prognosis patients, who represent the majority of candidates for these treatments...
  75. ncbi request reprint Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
    Robert J Motzer
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Lancet 372:449-56. 2008
    ..We did a phase III, randomised, double-blind, placebo-controlled trial of everolimus in patients with metastatic renal cell carcinoma whose disease had progressed on vascular endothelial growth factor-targeted therapy...
  76. ncbi request reprint Anti-VEGF therapy for renal cell carcinoma
    Bernard Escudier
    Immunotherapy and Innovative Therapy Unit, Institut Gustave Roussy, Paris 94805, France
    Clin Adv Hematol Oncol 5:530-1. 2007
  77. pmc Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial
    Tim Eisen
    The Royal Marsden Hospital NHS Trust, Sutton, Surrey, UK
    J Natl Cancer Inst 100:1454-63. 2008
    ..It is not known how older patients respond to targeted therapy...
  78. ncbi request reprint [Clinical results of Nexavar for the treatment of kidney cancer]
    Bernard Escudier
    Prog Urol 17:150-3. 2007
  79. ncbi request reprint Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer
    Ronald Bukowski
    CCF Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA
    Am J Clin Oncol 30:220-7. 2007
    ..The aim of the current study was to determine the impact of treatment with sorafenib versus placebo on renal cancer symptoms and quality of life (QOL)...
  80. ncbi request reprint Emerging efficacy endpoints for targeted therapies in advanced renal cell carcinoma
    Martin E Gore
    Department of Medicine, The Royal Marsden Hospital NHS Trust, London, England
    Oncology (Williston Park) 20:19-24. 2006
    ..Issues surrounding study endpoints and biologic efficacy markers for molecular targeted agents in RCC are discussed in this article, with a focus on results of the Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGETs)...
  81. ncbi request reprint [New entities in pathological classification and new therapeutic options in renal cell carcinoma]
    Jacques Olivier Bay
    Departement d Oncologie Medicale, Centre Jean Perrin, 58 rue Montalembert, 63000 Clermont Ferrand
    Bull Cancer 93:91-100. 2006
    ..Finally, we will present targeted therapy (antiangiogenic drugs and tyrosine kinase inhibitors) with the mechanisms of action, efficacy and appropriate use in the treatment of metastatic renal cell carcinoma...
  82. doi request reprint Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma
    Toni K Choueiri
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 26:127-31. 2008
    ..The activity of sunitinib and sorafenib in non-clear cell histologies has not been evaluated...
  83. ncbi request reprint Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors?
    Caroline Robert
    Ann Intern Med 143:313-4. 2005
  84. ncbi request reprint [Interleukin-2 and interferon in metastatic kidney cancer. Experience of the French Immunotherapy Group]
    Sylvie Negrier
    Departement d Oncologie Medicale, Centre Leon Berard, 28, rue Laennec, 69373 Lyon
    Prog Urol 12:213-8. 2002
    ..c. cytokine regimens are therefore fairly disappointing. These results were taken into account in the ongoing evaluation programme (Percy programme) based on patient selection as a function of prognostic factors...
  85. doi request reprint Familial non-VHL clear cell (conventional) renal cell carcinoma: clinical features, segregation analysis, and mutation analysis of FLCN
    Emma R Woodward
    Cancer Research UK Renal Molecular Oncology Group and Department of Medical and Molecular Genetics, University of Birmingham and West Midlands Regional Genetics Service, Birmingham Women s Hospital, United Kingdom
    Clin Cancer Res 14:5925-30. 2008
    ....
  86. ncbi request reprint Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells
    Nicolas van Baren
    Ludwig Institute for Cancer Research, 74 avenue Hippocrate, UCL7459, B 1200 Brussels, Belgium E mail
    J Clin Oncol 23:9008-21. 2005
    ....
  87. ncbi request reprint [Kidney tumors]
    Arnaud Mejean
    Prog Urol 17:1101-44. 2007
  88. ncbi request reprint Membrane-bound interleukin (IL)-15 on renal tumor cells rescues natural killer cells from IL-2 starvation-induced apoptosis
    Sebastian Wittnebel
    Institut National de la Santé et de la Recherche Médicale U753, France
    Cancer Res 67:5594-9. 2007
    ..Masking of MbIL-15 with soluble IL-15Ralpha molecules restored NK cell apoptosis. These findings suggest that IL-15 produced by renal tumor cells is involved in the maintenance of active NK cells at the tumor site...
  89. ncbi request reprint Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie
    Sylvie Negrier
    Department of Biostatistics, Centre Leon Berard, 28 rue Laennec, 69373 Lyon Cedex 08 France
    World J Urol 23:161-5. 2005
    ..Patients who combine at least three of these factors have over 80% probability of rapid progression despite treatment. We think that these results must be taken into account for cytokine treatment decision...
  90. ncbi request reprint Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma
    Wim H J Kruit
    Erasmus Medical Center Daniel den Hoed Cancer Center, Department of Internal Oncology, Rotterdam, The Netherlands
    Int J Cancer 117:596-604. 2005
    ....
  91. doi request reprint An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial
    Christopher Wood
    M D Anderson Cancer Center, Houston, TX, USA
    Lancet 372:145-54. 2008
    ....